Sysmex Medical Scientific Department Presentations at Euromedlab 2013

Norderstedt, Germany, 28 May 2013 - The Sysmex Europe Medical Scientific Department gave four exciting presentations at Euromedlab in Milan last week. They were attended by over 500 people across two sessions. The presentations addressed the latest findings in laboratory diagnostics developed in cooperation with Sysmex’s R&D and Clinical Management Concepts departments in Kobe, Japan. Those attending included prime decision-makers from laboratories across Europe and the world looking to improve the economic viability and clinical significance of their laboratories.

The world of laboratory diagnostics is changing both out of necessity and for good reason. Economic factors are driving laboratories to seek greater financial efficiency. Innovations by companies like Sysmex are improving the clinical significance and effectiveness of automated haematology and other diagnostic sciences. The content of the presentations at Euromedlab in Milan shows that there are exciting improvements available for immediate use and equally exciting new developments in the pipeline.

On Wednesday afternoon, Professor Machin from University College London Hospital kicked off the Sysmex scientific sessions with a talk on the issues related to measuring thrombocytes and how the use of the platelet-fluorescence parameter available on Sysmex’s new XN-Series can help indicate at an earlier stage whether a therapy is beneficial to a patient. Next, Dr Julia Dittmann introduced a new Sysmex software algorithm that will better answer the two key questions any clinician has for thrombocyte measurement: whether the patient is suffering from thrombocytopenia present, and whether a treatment is effective and the patient’s condition is improving. The new algorithm delivers greater clinical significance without increased costs – addressing both key needs of laboratory stakeholders.

On Thursday afternoon, two experts from Erasmus University Hospital in Rotterdam, the Netherlands discussed the latest developments in Sysmex’s research related to body fluids. Cherina Flemming spoke about body fluids in general, their sources in diagnostics and the issues measuring them. She also showed that, using chamber counting and cytospin morphology, the results of Sysmex’s XN-Series’ measurement are equally effective as the reference method. To close the sessions, Dr de Jonge provided an exciting insight into some initial results from the XN-Series research mode. In this mode, the XN is capable of differentiating leucocytes, counting erythrocytes to zero and counting pathological reactive activated cells. With further substantiation, this means clinicians will be able to identify brain bleeding (SAAH) with high sensitivity and specificity, and differentiate between infectious and non-infectious CSFs.

About Sysmex
Sysmex Corporation is a world leader in clinical laboratory systemisation and solutions, including laboratory diagnostics, laboratory automation and clinical information systems. Sysmex focuses on technological leadership in diagnostic science and information tools that make a difference in the health of people worldwide. The company is also developing solutions in the life science field with a focus on diagnostic cancer management. Headquartered in Kobe, Japan, Sysmex has subsidiaries in North America, Latin America, Europe, China and Asia Pacific and employs more than 5,000 employees worldwide.

Sysmex Europe GmbH
Bornbach 1
22848 Norderstedt

Phone: +49 (40) 527 26 0
www.sysmex-europe.com

This release was published on openPR.